Potent and Orally Bioavailable Antiplatelet Agent, PLD-301, with the Potential of Overcoming Clopidogrel Resistance

Author(s): Jingyu Chen, Michael Zhiyan Wang

Journal Name: Letters in Drug Design & Discovery

Volume 13 , Issue 3 , 2016

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


PLD-301, a phosphate prodrug of clopidogrel thiolactone discovered by Prelude Pharmaceuticals with the aim to overcome clopidogrel resistance, was evaluated for its in vivo inhibitory effect on ADP-induced platelet aggregation in rats. The potency of PLD-301 was similar to that of prasugrel, but much higher than that of clopidogrel. The results of pharmacokinetic analysis showed that the oral bioavailability of clopidogrel thiolactone converted from PLD-301 was 4- to 5-fold higher than that of the one converted from clopidogrel, suggesting that in comparison with clopidogrel, lower doses of PLD-301 could be used clinically. In summary, PLD-301 presents a potent and orally bioavailable antiplatelet agent that might have some advantages over clopidogrel, such as overcoming clopidogrel resistance for CYP2C19-allele loss-of-function carriers, and lowering dose-related toxicity due to a much lower effective dose.

Keywords: Clopidogrel, active metabolite, drug resistance, platelet ADP receptor, platelet aggregation, thrombosis.

open access plus

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Published on: 30 July, 2015
Page: [250 - 254]
Pages: 5
DOI: 10.2174/1570180812666150730221941

Article Metrics

PDF: 89
PRC: 1